These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 13634110)

  • 1. Effect of filtration procedures on immunogenic activity and safety of formalinized poliomyelitis vaccine (Salk type).
    GOLDBLUM N; MERCADO A; FOGEL A; CYMBALISTA S
    Proc Soc Exp Biol Med; 1959 Feb; 100(2):276-9. PubMed ID: 13634110
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody response of newborns to formalinized poliomyelitis vaccine (Salk type).
    RANNON L; GOLDBLUM N; SKALSKA P; GOTLIEB A
    Am J Hyg; 1960 Sep; 72():244-9. PubMed ID: 13739498
    [No Abstract]   [Full Text] [Related]  

  • 3. Production of formalinized poliomyelitis vaccine (Salk-type) on a semi-industrial scale.
    GOLDBLUM N; GOTLIEB T; MILLER G
    Bull World Health Organ; 1957; 17(6):1001-23. PubMed ID: 13511145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of infants with formalinized poliomyelitis vaccine (Salk type).
    SPIGLAND I; GOLDBLUM N
    Pediatrics; 1960 May; 25():812-21. PubMed ID: 13833339
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antibody response to anti-poliomyelitis vaccine (Salk type) in a group of children in the first 4 years of life].
    ODDO FG; FLACCOMIO R; PRIOLO A; SANTAMAURA S
    Riv Ist Sieroter Ital; 1959; 34():225-35. PubMed ID: 14428254
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antibody response of infants to a "booster" dose of the Salk type of poliomyelitis vaccine given from 5 to 6 months after early primary immunization].
    MORRONE G; NUNZIATA B
    Pediatria (Napoli); 1961; 69():851-6. PubMed ID: 14476315
    [No Abstract]   [Full Text] [Related]  

  • 7. [On the antibody response to basic immunizing treatment carried out with 2 or 3 injections of antipoliomyelitic vaccine (Salk type)].
    SANTOPADRE G; CASAROSA S; RUSCHI A; ZERBONI R
    Riv Ital Ig; 1961; 21():192-204. PubMed ID: 14497064
    [No Abstract]   [Full Text] [Related]  

  • 8. Observations on the potency and safety of poliomyelitis vaccine (Salk type) currently used.
    SUNADA K; GERLOFF RK; BROCK D; HOPKEY I; EKLUND CM; KLOTZ AW
    AMA J Dis Child; 1958 Aug; 96(2):125-30. PubMed ID: 13558864
    [No Abstract]   [Full Text] [Related]  

  • 9. Unpredictability of antibody response of infants to injections of Salk poliomyelitis vaccine.
    CRAMBLETT HG; FOMON SJ
    J Pediatr; 1961 Jun; 58():779-84. PubMed ID: 13696225
    [No Abstract]   [Full Text] [Related]  

  • 10. Complement-fixing antigens of living and inactivated poliovirus. II. Complement-fixing activity of poliomyelitis vaccine and its relation to immunogenic potency.
    WARREN J; HARE JD; GOLDMAN C
    Am J Public Health Nations Health; 1959 Jan; 49(1):53-61. PubMed ID: 13617534
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in Macaca mulatta.
    HENNEBERG G; DRESCHER J; GODGLUECK G; GRUETZNER L
    Am J Hyg; 1962 Jan; 75():44-55. PubMed ID: 13906466
    [No Abstract]   [Full Text] [Related]  

  • 12. A method for the rapid determination of immunogenic potency of poliomyelitis vaccines by single vaccination of white rats.
    GHENDON IZ; MARCHENKO AT
    Acta Virol; 1959 Oct; 3():250-2. PubMed ID: 13849934
    [No Abstract]   [Full Text] [Related]  

  • 13. The relationship between specific skin reaction and neutralizing antibody titers in the young infant following immunization with poliomyelitis (Salk-type) vaccine.
    MORRONE G; NUNZIATA B
    Ann Paediatr; 1961; 196():389-98. PubMed ID: 13772899
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibody response to Salk vaccine in Norwegian school children.
    ULSTRUP JC; MEMMER R
    Arch Gesamte Virusforsch; 1959; 9():343-7. PubMed ID: 13840329
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of guinea pigs in tests for immunogenic capacity of poliomyelitis virus preparations.
    GARD S; WESSLEN T; FAGRAEUS A; SVEDMYR A; OLIN G
    Arch Gesamte Virusforsch; 1956; 6(5):401-11. PubMed ID: 13340710
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody response to increased amounts of poliomyelitis vaccine.
    BARNETT EV; BARON S
    Am J Hyg; 1960 Jan; 71():59-68. PubMed ID: 13796911
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody response in infants to the poliomyelitis component of a quadruple vaccine.
    HILLARY IB; MEENAN PN; GOFFE AP; KNIGHT GJ; KANAREK AD; POLLOCK TM
    Br Med J; 1962 Apr; 1(5285):1098-102. PubMed ID: 13907392
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody response to poliomyelitis vaccine administered by jet injection.
    LIPSON MJ; CARVER DH; ELEFF MG; HINGSON RA; ROBBINS FC
    Am J Public Health Nations Health; 1958 May; 48(5):599-603. PubMed ID: 13521099
    [No Abstract]   [Full Text] [Related]  

  • 19. [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)].
    ENDERS-RUCKLE G; SIEGERT R
    Dtsch Med Wochenschr; 1961 Oct; 86():1999-2008. PubMed ID: 13890174
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvements in the tissue culture safety testing of Salk vaccines.
    FRENCH RC; ARMSTRONG RE; YAROSH W
    Can J Microbiol; 1959 Oct; 5():453-9. PubMed ID: 13824871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.